You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 206 No. 12, December 16, 1968 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cephaloglycin

Clinical and Laboratory Experience With an Orally Administered Cephalosporin

Warren D. Johnson, MD; Jeffrey M. Applestein, MD; Donald Kaye, MD

JAMA. 1968;206(12):2698-2702.


Abstract

Cephaloglycin was evaluated in vitro and in the treatment of urinary tract infection. Over 90% of strains of Escherichia coli, Proteus mirabilis, and Klebsiella-Aerobacter were inhibited by concentrations of cephaloglycin achieved in the urine of patients receiving cephaloglycin as therapy for urinary tract infections. Peak serum concentrations of cephaloglycin inhibited all strains of group A streptococci and Diplococcus pneumoniae and some strains of Staphylococcus aureus, E coli, and p mirabilis. Twenty-three patients with urinary tract infection were treated with cephaloglycin. Most of the patients had structural abnormalities or chronic infection of the urinary tract. All patients were free of bacteriuria during therapy and 11 patients (48%) were abacteriuric one month after discontinuation of therapy. Diarrhea and eosinophilia were the only side effects noted and did not constitute a major problem.



Author Affiliations

From the Department of Medicine, the New York Hospital— Cornell Medical Center, New York.


Footnotes

Reprint requests to 525 E 68th St, New York 10021 (Dr. Johnson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cephalosporin-Associated Pseudomembranous Colitis
Tures et al.
JAMA 1976;236:948-949.
ABSTRACT  

Guide to Drug Usage in Adult Patients With Impaired Renal Function: A Supplement
Bennett et al.
JAMA 1973;223:991-997.
ABSTRACT  

Cephaloglycin in Pediatric Patients
Matsen
Arch Pediatr Adolesc Med 1971;121:38-42.
ABSTRACT  

The Cephalosporins: Microbiological, Chemical, and Pharmacological Properties and Use in Chemotherapy of Infection
WEINSTEIN and KAPLAN
ANN INTERN MED 1970;72:729-739.
ABSTRACT  

Oral Cephalexin and Ampicillin: Antimicrobial Activity, Recovery in Urine, and Persistence in Blood of Uremic Patients
KUNIN and FINKELBERG
ANN INTERN MED 1970;72:349-356.
ABSTRACT  

Clinical and In Vitro Evaluation of Cephalexin: A New Orally Administered Cephalosporin Antibiotic
Levison et al.
JAMA 1969;209:1331-1336.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1968 American Medical Association. All Rights Reserved.